Production (Stage)
Aurinia Pharmaceuticals Inc.
AUPH
$7.99
-$0.16-1.96%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 39.85M | 5.75M | -22.55M | -50.35M | -62.56M |
| Total Depreciation and Amortization | 19.45M | 19.45M | 19.53M | 19.90M | 15.78M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 13.75M | 13.74M | 29.21M | 28.18M | 29.51M |
| Change in Net Operating Assets | -8.76M | 5.45M | 2.40M | 547.00K | -3.12M |
| Cash from Operations | 64.29M | 44.39M | 28.59M | -1.72M | -20.39M |
| Capital Expenditure | -298.00K | -293.00K | -311.00K | -206.00K | -383.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 21.36M | 39.56M | -5.91M | -15.14M | 18.05M |
| Cash from Investing | 21.06M | 39.26M | -6.22M | -15.35M | 17.67M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -11.98M | -11.99M | -15.50M | -16.03M | -12.80M |
| Issuance of Common Stock | 18.53M | 14.77M | 10.09M | 11.00M | 11.06M |
| Repurchase of Common Stock | -89.93M | -51.87M | -26.21M | -26.21M | -20.08M |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -83.38M | -49.09M | -31.62M | -31.23M | -21.82M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 1.97M | 34.56M | -9.26M | -48.30M | -24.54M |